Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E3SH
|
|||
| Former ID |
DCL000914
|
|||
| Drug Name |
Panobinostat
|
|||
| Synonyms |
Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Approved | [1] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 3 | [2], [3] | ||
| Primary myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 2 | [2], [4] | ||
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23N3O2
|
|||
| Canonical SMILES |
CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO
|
|||
| InChI |
1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
|
|||
| InChIKey |
FPOHNWQLNRZRFC-ZHACJKMWSA-N
|
|||
| CAS Number |
CAS 404950-80-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12015928, 15274143, 17195129, 43530200, 57372035, 62645030, 75710455, 81055018, 87226499, 87350378, 93300558, 99436947, 103632713, 109693246, 114788640, 118049495, 123051106, 124756947, 125163753, 126657606, 126666979, 126731350, 127342240, 127342241, 131404644, 131465111, 134339363, 134964365, 135252712, 136340102, 136345863, 136367899, 136379865, 136920346, 137003312, 140114795, 143497586, 144116133, 152212116, 152237701, 152258137, 152344186, 160646976, 162011828, 162037392, 162193612, 163312349, 164194122, 164825246, 172086282
|
|||
| ChEBI ID |
CHEBI:85990
|
|||
| ADReCS Drug ID | BADD_D01667 ; BADD_D02454 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7489). | |||
| REF 3 | Progress of HDAC inhibitor panobinostat in the treatment of cancer. Curr Drug Targets. 2014 Jun;15(6):622-34. | |||
| REF 4 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 5 | Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. | |||
| REF 6 | Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs. 2008 Jun;13(2):345-61. | |||
| REF 7 | Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. | |||
| REF 8 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.